INAB vs TMO vs JPM vs ILMN vs BAC

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Bank of America Corporation (BAC) offers the better valuation at 14. 9x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bank of America Corporation (BAC) is the cheapest at 14.

9x versus Illumina, Inc. at 30. 1x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 83x versus Thermo Fisher Scientific Inc. 's 9. 00x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +126. 7%, compared to -99. 5% for IN8bio, Inc. (INAB). Over 10 years, the gap is even starker: JPM returned +492. 1% versus INAB's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.

86β versus IN8bio, Inc. 's 1. 89β — meaning INAB is approximately 119% more volatile than BAC relative to the S&P 500. On balance sheet safety, IN8bio, Inc. (INAB) carries a lower debt/equity ratio of 10% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -678. 9% for IN8bio, Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 0% for IN8bio, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 0. 0% for INAB. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 83x versus Thermo Fisher Scientific Inc. 's 9. 00x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 7x forward P/E versus 31. 5x for Illumina, Inc. — 18. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 26. 9% to $599. 70.

In this comparison, BAC (2.

2% yield), JPM (1. 8% yield), TMO (0. 4% yield) pay a dividend. INAB, ILMN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 8% yield, +492. 1% 10Y return). IN8bio, Inc. (INAB) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +492. 1%, INAB: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INAB (Healthcare) and TMO (Healthcare) and JPM (Financial Services) and ILMN (Healthcare) and BAC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INAB is a small-cap quality compounder stock; TMO is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock; ILMN is a mid-cap quality compounder stock; BAC is a large-cap deep-value stock. JPM, BAC pay a dividend while INAB, TMO, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.